A Phase II, Randomized, Open-Label Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents with Tuberculous Meningitis: Improved Management with Antimicrobial AGents Isoniazid rifampiciN LinEzolid for TBM (IMAGINE-TBM)

ational Institute of Allergy and Infectious Diseases0 个研究点目标入组 330 人开始时间: 2023年5月18日最近更新: 2024年3月4日

适应症

试验速览

阶段: 2 期
状态: 尚未招募
发起方
入组人数: 330

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 13 Year(s) 至 18 Year(s)（—）
性别: All

入选标准

•Definite, probable, or possible TBM diagnosis wherein the participant is being committed to a full course of SOC anti-TB treatment for TBM in the setting of routine care. CSF, imaging, laboratory, and other results used to determine definite, probable, or possible TBM can be from testing performed as part of routine care, as long as obtained within 21 days prior to study entry
•Persons aged =15 years
•Absence of HIV-1 infection, as documented by any licensed rapid HIV test or HIV-1 enzyme or chemiluminescence immunoassay (E/CIA) test kit, within 30 days prior to study entry, OR
•HIV-1 infection, documented by any licensed rapid HIV test or HIV-1 E/CIA test kit at any time prior to entry and confirmed by a licensed Western blot or a second antibody test by a method other than the initial rapid HIV and/or E/CIA, or by HIV-1 antigen or plasma HIV-1 RNA viral load. Two or more HIV-1 RNA viral loads of >1,000 copies/mL are also acceptable as documentation of HIV-1 infection, or documentation of HIV diagnosis in the medical record by a healthcare provider
•Documentation within 3 days prior to study entry of stage of disease using BMRC TBM grade:
•Grade I: Glasgow Coma Score 15, no focal neurological deficits, Grade II: Glasgow Coma Score 11-14 or 15 with focal neurological deficits, Grade III: Glasgow Coma Score =10
•The following laboratory values obtained within 3 days prior to study entry:
•Serum creatinine =1.8 times upper limit of normal (ULN), Hemoglobin =8.0 g/dL for men, =7.5 g/dL for women
•Absolute neutrophil count =600/mm3, Platelet count =60,000/mm3, Alanine aminotransferase (ALT) =3 x ULN
•Total bilirubin =2 x ULN
•For participants of reproductive potential who have not been post-menopausal for at least 24 consecutive months (i.e., no menses within the preceding 24 months), or participants who have not undergone surgical sterilization, hysterectomy, bilateral salpingectomy, bilateral oophorectomy, or tubal ligation, documentation of a pregnancy while receivingstudy treatment and for 30 days after stopping study treatment

排除标准

•More than 14 cumulative days of first-line TB medications, including but not limited to INH, RIF, EMB, and PZA, received within 90 days prior to study entry
•Known current or previous drug resistant TB infection (i.e., resistance to one or more first-line TB medications, including but not limited to INH, RIF, EMB, LZD and PZA)
•Known allergy/sensitivity or any hypersensitivity to components of study TB drugs (INH, RIF, LZD, PZA, and EMB) or their formulation
•For participants who are able to undergo the Brief Peripheral Neuropathy Screen (BPNS) within 21 days prior to study entry, Grade 3 subjective peripheral neuropathy score on the BPNS AND EITHER vibratory loss OR absent ankle jerks
•Expected concomitant use or use up to 21 days prior to study entry of monoamine oxidase inhibitors or selective serotonin reuptake inhibitors, or concomitant use of any other drug with significant interaction with the study drugs (See protocol)
•For participants with HIV and ART-naïve, planned initiation of ART during the first 4 weeks after randomization
•For participants with HIV and on ART that includes a protease inhibitor, nevirapine, or other prohibited ART (see protocol), contraindication to switching to an acceptable alternative regimen (e.g., efavirenz, high-dose raltegravir or dolutegravir with nucleoside reverse transcriptase inhibitors, as per local SOC) prior to randomization. TB treatment, including study drugs, should be started as soon as possible
•Contraindication to LP at discretion of treating clinician (e.g., unequal pressures between intracranial compartments due to mass lesion, non-communicating hydrocephalus)
•Positive cryptococcal antigen, gram stain, bacterial culture, or other test result obtained from a CSF specimen collected within 21 days prior to entry as part of routine care indicating CNS infection with a pathogen other than Mtb (e.g., cryptococcal meningitis, bacterial meningitis).

研究者

发起方

ational Institute of Allergy and Infectious Diseases

相似试验

尚未招募

2 期

A5384: Open lable study to compare a 6-month regimen of high-dose of anti TB medicationsagainst 9 month standard of care (SOC) regimen for the treatment of tuberculous meningitis(TBM)

CTRI/2023/05/053012IH DAIDS

Unknown

2 期

A multicenter phase 2 trial evaluating the efficacy and safety of oral CA-170 in patients with lung cancer, head and neck / oral cavity cancer, MSI-H positive cancers and Hodgkin lymphoma.

CTRI/2017/12/011026Aurigene Discovery Technologies Limited62

进行中（未招募）

1 期

Study to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine Given With Prevnar 13 in Healthy InfantsPneumococcal InfectionsMedDRA version: 21.1Level: PTClassification code 10069578Term: Pneumococcal immunisationSystem Organ Class: 10042613 - Surgical and medical procedures

EUCTR2020-005039-59-Outside-EU/EEAPfizer, Inc.

招募中

1 期

A trial to find the optimal dose of DB-OTO in infants and children with hearing loss (CHORD)Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)MedDRA version: 20.0Level: LLTClassification code: 10011874Term: Deaf Class: 10013993

CTIS2024-511342-40-00Regeneron Pharmaceuticals Inc.22

进行中（未招募）

1 期

MK-3682B (MK-5172 + MK-3682 + MK-8408 Fixed Dose Combination (FDC)) in HCV GT1 or GT3 DAA FailuresHepatitis C infection

EUCTR2015-001483-19-SEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc200